Therapeutic Thursday: Launch Day Strength
Analysts see mega-blockbuster potential in Revolution’s Rasonque, but its CEO is tempering expectations. Sometimes the smartest move after a record launch is to ask everyone to hold the applause.
Cancer drug development, from early trials to approvals and launches. Covers solid tumors and blood cancers, and the companies and regulators shaping both.
Analysts see mega-blockbuster potential in Revolution’s Rasonque, but its CEO is tempering expectations. Sometimes the smartest move after a record launch is to ask everyone to hold the applause.
Genmab halves the risk of death in head and neck cancer, the KRAS G12C frontline race heats up, GSK breaks an osteosarcoma drought, and Vanda targets GLP-1 nausea.
Two papers came out of Madrid. Pfizer’s antibody-drug conjugate (ADC) missed in Phase III lung cancer and is pointing to a second-line subgroup for partial credit, while GSK’s ovarian cancer ADC has a strong early answer and is promising the working in Phase III.
A standing ovation for new small cell lung cancer data led an ESMO weekend in which the winning regimens kept asking less of patients: less chemotherapy, less time in the monitoring chair, fewer people quitting treatment over side effects.
Your cheat sheet to ESMO 2026: the nine oncology readouts investors are watching, and why the fine print decides the winners.
BMS’s myeloma pill and Merck’s eye drug both hit their endpoints this week and both left questions unanswered, while investors mapped out a US–China future for drug development.
ADARx, the year's 22nd US drug developer IPO, closed Oct. 1 above its offer price. The bigger story is life after opening night: one hair loss developer ended Oct. 1 near seven times its offer price, and listed companies are finding new money on terms that need a careful read.
Biopharma VC had a quiet summer and September is making up for it with five mega rounds in the first half of the month, matching July and August totals combined. The number is striking but the composition is just as interesting.
Four WCLC readouts, one message: new ADCs and TKIs are beating the standard of care in both non-small cell and small-cell lung cancer.
The first targeted therapy for pancreatic cancer just got approved, with overall survival data that doubled chemotherapy and a pipeline that stretches into lung cancer and beyond.
Dealmaking has reached its highest value since 2019 and the field of buyers has widened. The smartest money is still going early.
Moderna's mRNA platform has spent decades in development and years in respiratory medicine. This week it got its first Phase III win in oncology, and the full data have not even landed yet.